PAR2 impairs glucose uptake and insulin sensitivity in NAFLD by decreasing GLUT2 expression through the Gq-MAPK-FoxA3 pathway, and inhibiting insulin-Akt signaling via the Gq-calcium-CaMKK2 pathways (Shearer et al., 2022). This evidence concerns the gene FOXA3 and metabolic dysfunction-associated steatotic liver disease.